MY118526A - Method for improving the pharmacokinetics of tipranavir - Google Patents
Method for improving the pharmacokinetics of tipranavirInfo
- Publication number
- MY118526A MY118526A MYPI99004794A MYPI9904794A MY118526A MY 118526 A MY118526 A MY 118526A MY PI99004794 A MYPI99004794 A MY PI99004794A MY PI9904794 A MYPI9904794 A MY PI9904794A MY 118526 A MY118526 A MY 118526A
- Authority
- MY
- Malaysia
- Prior art keywords
- tipranavir
- pharmacokinetics
- improving
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000838 tipranavir Drugs 0.000 title abstract 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10696398P | 1998-11-04 | 1998-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY118526A true MY118526A (en) | 2004-11-30 |
Family
ID=22314155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99004794A MY118526A (en) | 1998-11-04 | 1999-11-04 | Method for improving the pharmacokinetics of tipranavir |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6147095A (enExample) |
| EP (1) | EP1126847A1 (enExample) |
| JP (1) | JP2002528502A (enExample) |
| CN (1) | CN1154491C (enExample) |
| AU (1) | AU762349B2 (enExample) |
| BR (1) | BR9914940A (enExample) |
| CA (1) | CA2346131C (enExample) |
| CO (1) | CO5160321A1 (enExample) |
| HK (1) | HK1040625B (enExample) |
| MY (1) | MY118526A (enExample) |
| PE (1) | PE20001296A1 (enExample) |
| TW (1) | TW580387B (enExample) |
| WO (1) | WO2000025784A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| ATE381922T1 (de) * | 2000-10-31 | 2008-01-15 | Boehringer Ingelheim Pharma | Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren |
| US6500963B2 (en) | 2001-02-22 | 2002-12-31 | Boehringer Ingelheim Pharma Kg | Process for preparing optically active dihydropyrones |
| DE10108470A1 (de) * | 2001-02-22 | 2002-09-05 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung optisch aktiver Dihydropyrone |
| US20040197321A1 (en) * | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| US20030180279A1 (en) * | 2002-03-19 | 2003-09-25 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| EP1575595A1 (en) * | 2002-12-16 | 2005-09-21 | Boehringer Ingelheim International GmbH | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
| US20050020517A1 (en) * | 2002-12-16 | 2005-01-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Treatment of HIV infection through combined administration of tipranavir and capravirine |
| WO2004087139A1 (en) * | 2003-03-27 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Antiviral combination of tipranavir and a further antiretroviral compound |
| AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
| CA2583187A1 (en) * | 2004-11-08 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and etravirine |
| JP2008520672A (ja) * | 2004-11-16 | 2008-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法 |
| US20060128733A1 (en) * | 2004-11-19 | 2006-06-15 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and reverset |
| US20060122220A1 (en) * | 2004-11-19 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and UK-427,857 |
| CA2585663A1 (en) * | 2004-12-01 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and sch-417690 |
| JP2008521898A (ja) * | 2004-12-01 | 2008-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法 |
| US20060142344A1 (en) * | 2004-12-01 | 2006-06-29 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and GW695634 |
| KR101518079B1 (ko) | 2007-03-12 | 2015-05-06 | 넥타르 테라퓨틱스 | 올리고머-프로테아제 억제제 컨주게이트 |
| EP2262538B1 (en) * | 2008-03-12 | 2014-12-10 | Nektar Therapeutics | Oligomer-amino acid conjugate |
| US20100021505A1 (en) * | 2008-07-28 | 2010-01-28 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| US20120108501A1 (en) | 2009-06-12 | 2012-05-03 | Nektar Therapeutics | Protease Inhibitors |
| BR112012024522A2 (pt) * | 2010-04-02 | 2017-08-08 | Phivco 1 Llc | combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio |
| CN104160274A (zh) * | 2011-05-30 | 2014-11-19 | 奥德特里克公司 | 通过照护点药物动力学曲线分析进行治疗药物监测和投配的方法与组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5932570A (en) * | 1996-11-08 | 1999-08-03 | Dupont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors |
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
-
1999
- 1999-10-29 JP JP2000579225A patent/JP2002528502A/ja active Pending
- 1999-10-29 WO PCT/US1999/021469 patent/WO2000025784A1/en not_active Ceased
- 1999-10-29 US US09/430,742 patent/US6147095A/en not_active Expired - Lifetime
- 1999-10-29 EP EP99971319A patent/EP1126847A1/en active Pending
- 1999-10-29 BR BR9914940-0A patent/BR9914940A/pt not_active Application Discontinuation
- 1999-10-29 HK HK02102194.8A patent/HK1040625B/zh not_active IP Right Cessation
- 1999-10-29 CN CNB998123587A patent/CN1154491C/zh not_active Expired - Lifetime
- 1999-10-29 CA CA2346131A patent/CA2346131C/en not_active Expired - Lifetime
- 1999-10-29 AU AU14404/00A patent/AU762349B2/en not_active Expired
- 1999-11-03 PE PE1999001100A patent/PE20001296A1/es not_active Application Discontinuation
- 1999-11-04 CO CO99069669A patent/CO5160321A1/es unknown
- 1999-11-04 MY MYPI99004794A patent/MY118526A/en unknown
- 1999-11-04 TW TW088119229A patent/TW580387B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20001296A1 (es) | 2000-11-23 |
| US6147095A (en) | 2000-11-14 |
| CO5160321A1 (es) | 2002-05-30 |
| CN1324237A (zh) | 2001-11-28 |
| AU762349B2 (en) | 2003-06-26 |
| JP2002528502A (ja) | 2002-09-03 |
| EP1126847A1 (en) | 2001-08-29 |
| CA2346131C (en) | 2013-01-15 |
| HK1040625B (zh) | 2005-04-01 |
| TW580387B (en) | 2004-03-21 |
| AU1440400A (en) | 2000-05-22 |
| WO2000025784A1 (en) | 2000-05-11 |
| HK1040625A1 (en) | 2002-06-21 |
| CN1154491C (zh) | 2004-06-23 |
| CA2346131A1 (en) | 2000-05-11 |
| BR9914940A (pt) | 2001-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| UA56989C2 (uk) | ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ | |
| IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
| ZA977783B (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| UA41879C2 (uk) | Засіб для лікування мотонейронових захворювань | |
| CA2426703A1 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
| GB2368525A (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| AU7040201A (en) | A new use for deferiprone | |
| GB0020504D0 (en) | Therapeutic method | |
| PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
| WO2001045715A3 (en) | Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain | |
| MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
| EP0744176A3 (en) | Methods for inhibiting bone loss | |
| YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
| WO1999065475A3 (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| EP0799618A3 (en) | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer | |
| EP0967276A3 (en) | Anti-tumor agent comprising salmosin | |
| BG106151A (en) | Pharmaceutical complex | |
| EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
| IL126158A0 (en) | Method for treating substance abuse |